Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 36Magnetic Resonance Spectroscopy 23Gemcitabine 19Specimen Handling 15Nivolumab 12Carboplatin 12Surveys and Questionnaires 11Paclitaxel 11Cetuximab 11Early Intervention, Educational 10Bevacizumab 10Standard of Care 9Cyclophosphamide 9Cisplatin 9Radiosurgery 8Methods 8Fluorouracil 8Docetaxel 8Blood Specimen Collection 8Psychiatric Rehabilitation 7Pemetrexed 7sargramostim 6aldesleukin 6Taxes 6Injections 6Fluorodeoxyglucose F18 6Educational Status 6Drug Therapy 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × lonafarnib × Gastrointestinal × Clear all
NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Emory University

Phase 1 Terminated
38 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡